Humulin N (Insulin Human)

Humulin N is indicated for the long‑term control of blood glucose in adults and children with diabetes.

• Basal insulin therapy for type 1 diabetes mellitus when combined with rapid‑acting insulin.
• Basal insulin therapy for type 2 diabetes mellitus as part of a multi‑dose regimen.
• Adjunct to dietary management and exercise in patients requiring a steady insulin background.
• Use in insulin‑deficient states where a prolonged glucose‑lowering effect is desired.
• Replacement therapy for patients with inadequate endogenous insulin production.

• Humulin N delivers insulin human, which binds to insulin receptors on muscle, fat and liver cells. Receptor activation triggers the tyrosine‑kinase signaling cascade, promoting translocation of GLUT‑4 transporters to the cell surface and enhancing glucose uptake. In the liver, insulin suppresses gluconeogenesis and glycogenolysis, reducing endogenous glucose output. The neutral protamine formulation slows absorption, providing a relatively flat, long‑duration insulin effect.

Like all insulin products, Humulin N may be associated with adverse reactions that vary in frequency and severity.

Common

• Hypoglycemia (low blood glucose) – the most frequently reported event.
• Injection site reactions such as redness, swelling, or itching.
• Weight gain associated with improved glycemic control.
• Lipodystrophy (localized fat accumulation or loss) at injection sites.
• Nausea or abdominal discomfort.
• Headache.

Serious

• Severe hypoglycemia leading to loss of consciousness or seizures.
• Allergic reactions including urticaria, angioedema, or anaphylaxis.
• Hypersensitivity with eosinophilia or fever.
• Insulin edema causing peripheral swelling.
• Serum electrolyte disturbances such as hypokalemia.

When prescribing or using Humulin N, clinicians and patients should consider several safety precautions to minimize risks.

• Monitor blood glucose regularly to detect and treat hypoglycemia promptly.
• Adjust dose during periods of illness, fasting, or changes in physical activity.
• Use caution in patients with renal or hepatic impairment, as insulin clearance may be reduced.
• Avoid use in individuals with known hypersensitivity to insulin human or any formulation component.
• Pregnancy and lactation status should be evaluated; insulin requirements may change.
• Educate patients on proper injection technique to reduce lipodystrophy.
• Review concomitant medications that can mask hypoglycemia symptoms.

Humulin N can interact with other medicines, affecting glucose control or insulin activity.

Avoid

• Concurrent use of sulfonylureas or meglitinides, which also lower blood glucose.
• Combination with high‑dose beta‑blockers that may mask hypoglycemia signs.
• Co‑administration with systemic corticosteroids that can increase insulin resistance.

Use with caution

• Concurrent thiazide diuretics, which may raise blood glucose levels.
• Concurrent ACE inhibitors or ARBs, which can potentiate insulin’s glucose‑lowering effect.
• Concurrent oral contraceptives or hormone replacement therapy, which may alter insulin requirements.
• Concurrent alcohol intake, which can cause unpredictable glucose fluctuations.